BLTE

Belite Bio Inc ADR

BLTE, USA

Belite Bio, Inc, a clinical stage biopharmaceutical drug development company, engages in the research and development of novel therapeutics targeting retinal degenerative eye diseases with unmet medical needs in the United States. Its lead product candidate is Tinlarebant (LBS-008), an orally administered, which is in phase 3 clinical trial as an early intervention for maintaining the health and integrity of retinal tissues in stargardt disease type 1 and geographic atrophy patients. The company also develops LBS-009, an anti-retinol-binding protein 4 oral therapy, which is in preclinical development targeting liver disease, including non-alcoholic fatty liver disease, nonalcoholic steatohepatitis, and type 2 diabetes, as well as gout. Belite Bio, Inc was founded in 2016 and is based in San Diego, California. Belite Bio, Inc is a subsidiary of Lin Bioscience International Ltd.

https://www.belitebio.com

Stock Price

$0.00

0%

increase compared to yesterday.

Dividend

Frequency:

N/A

Rate:

N/A

Next Payout:

N/A
BLTE
stock
BLTE

Avoiding Lag: Real-Time Signals in (BLTE) Movement Stock Traders Daily

Read more →
BLTE
stock
BLTE

Belite Bio, Inc. Sponsored ADR (NASDAQ:BLTE) Given Consensus Recommendation of “Moderate Buy” by Brokerages Defense World

Read more →

Showing 2 of 10

Analyst Ratings & Sentiment

(Last Updated 2025-09-30)

Rating:

STRONG BUY

Target Price:

$185.2857

Analyst Picks

Strong Buy

3

Buy

2

Hold

0

Sell

0

Strong Sell

0

Sentiment:

Bullish

Finn Analysis

(Last Updated 2025-09-30)

Health Score

Price to Book Ratio (P/B)

-

Very High

18.95

Low 1

High 3

Return on Equity (ROE)

-

Very Low

-7.91 %

Low 5%

High 25%

Return on Assets (ROA)

-

Very Low

-7.68 %

Low 2%

High 10%

Debt to Equity

-

Very High

0.03

Low 1

High 0.3

Investors

* Institutions hold a combined 0.35% of the total shares of Belite Bio Inc ADR

1.

State Street Corp

(0.0621%)

since

2025/06/30

2.

Geode Capital Management, LLC

(0.0395%)

since

2025/06/30

3.

SPDR® Portfolio Emerging Markets ETF

(0.0336%)

since

2025/08/29

4.

Marshall Wace Asset Management Ltd

(0.0291%)

since

2025/06/30

5.

Citadel Advisors Llc

(0.0229%)

since

2025/06/30

7.

JPMorgan Chase & Co

(0.0208%)

since

2025/06/30

8.

Fidelity Nasdaq Composite Index

(0.0207%)

since

2025/07/31

9.

Fidelity Nasdaq Composite ETF

(0.0188%)

since

2025/08/29

10.

Renaissance Technologies Corp

(0.0132%)

since

2025/06/30

11.

BNP Paribas Arbitrage, SA

(0.0101%)

since

2025/06/30

12.

Cubist Systematic Strategies, LLC

(0.0088%)

since

2025/06/30

13.

UBS Group AG

(0.0072%)

since

2025/06/30

14.

Virtus LifeSci Biotech Clinical Trls ETF

(0.0061%)

since

2025/08/29

15.

ActivePassive International Equity ETF

(0.0055%)

since

2025/08/29

16.

GAMMA Investing LLC

(0.0049%)

since

2025/06/30

17.

Virtus Investment Advisors (VIA)

(0.0046%)

since

2025/06/30

18.

SPDR® S&P China ETF

(0.0043%)

since

2025/08/29

19.

Point72 Asset Management, L.P.

(0.004%)

since

2025/06/30

20.

Bank of America Corp

(0.0028%)

since

2025/06/30

21.

CIBC US Broad Market Index

(0.0024%)

since

2025/05/31

22.

JHVIT Total Stock Market Index I

(0.0017%)

since

2025/07/31

23.

Morgan Stanley - Brokerage Accounts

(0.0016%)

since

2025/06/30

25.

SBI Securities Co Ltd

(0.0002%)

since

2025/06/30

26.

Advisor Group Holdings, Inc.

(0%)

since

2025/06/30

27.

Goldman Sachs Group Inc

(0%)

since

2025/03/31

28.

Tower Research Capital LLC

(0%)

since

2025/06/30

29.

Ameriprise Financial Inc

(0%)

since

2025/06/30

30.

QRG QP: Emerging Markets ADR Beta

(0%)

since

2025/06/30

31.

QRG QP: Factor EM ADR VMQ

(0%)

since

2025/06/30

* Investors data is estimated based on stocks listed on Finnton that are currently held by Institution/Fund.

Earnings History

EPS ActualEPS EstimateEPS DifferenceSurprise Percent

Upcoming Earnings Release

Date

2025-12-31

EPS Estimate

-0.4825

Latest Release

Date

2025-09-30

EPS Actual

-0.65

EPS Estimate

-0.4975

EPS Difference

-0.1525

Surprise Percent

-30.6533%

Investing Fit Scorecard

(Last Updated 2025-09-30)

Deep Value
Weak Deep Value(3)
Defensive
Moderately Defensive(5)
Dividend
Weak Dividend Profile(1.5)
Economic Moat
Some Competitive Advantage(3.8)
GARP
Not Attractive for GARP(2)
Growth
Weak Growth Prospect(0.5)
Momentum
Moderate Momentum(4)
Net Net
Not Undervalued (Net-Net)(2.5)
Quality
Low Quality Business(2.5)
Value
Overpriced(3)

Income Statement

(Last Updated 2025-09-30)

Revenue

$ 0

Cost Of Revenue

$ 0

Gross Profit

$ 0

Operating Expenses

$ 0

Operating Income

$ 0

Interest Expense

$ 0

Pretax Income

$ 0

Net Income

$ 0

Income Tax Expense

$ 0

EBITDA

$ 0

Total Other Income Expense Net

$ 0

Earnings Per Share

0

Dividends Per Share

0

Shares Outstanding

0

Operating Margin

0%

Trend

Balance Sheet

(Last Updated 2025-09-30)

Cash

$ 0

Short Term Investments

$ 0

Receivables

$ 0

Inventories

$ 0

Total Current Assets

$ 0

Property Plant Equipment

$ 0

Total Assets

$ 0

Payables

$ 0

Short Term Debt

$ 0

Long Term Debt

$ 0

Total Liabilities

$ 0

Equity

$ 0

Trend

Cash Flow

(Last Updated 2025-09-30)

Net Income

$ 0

Depreciation

$ 0

Change In Working Capital

$ 0

Cash From Operations

$ 0

Capital Expenditures

$ 0

Cash From Investing

$ 0

Cash From Financing

$ 0

Net Change In Cash

$ 0

Trend

Disclaimer: Finnton is a stock screener tool provided for informational and educational purposes only. The data, analysis, and insights offered on this website do not constitute financial, investment, tax, or legal advice. Users are solely responsible for their own investment decisions, and Finnton makes no guarantees regarding the accuracy, completeness, or reliability of the information provided. Past performance is not indicative of future results. Always conduct your own research and consult with a licensed financial advisor before making any investment decisions.